Pharma & Biotech Global Week in Review 8 Dec 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

India: Supreme Court dismisses Bayer’ petition in patent linkage matter (Generic Pharmaceuticals and IP) (Spicy IP) (GenericsWeb) (SiNApSE)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.


WHO to define traditional medicines standards (IP Watch)

Getting the best medicines to market, not just the medicines with the best patents (America-Israel Patent Law)

A patent or a club? – Nova Biomedical fight for survival following patent threats from Abbott, Roche, Medtronic (IP Directions)

Pathogens and the Nagoya Protocol of the Convention on Biological Diversity (PatentlyBIOtech)

Australia: Federal Court punishes CSL for amendment delay: CSL Limited v Novo Nordisk Pharmaceuticals Pty Ltd (Patentology)

Australia: AusBiotech, legal academics and ARDR weigh in on gene patent debate (Patentology)

Australia: Gene patent amendment bill introduced (IP Whiteboard)

Australia: Gene patents inquiry report (IP Whiteboard)

Brazil: It’s a bird… it’s a plane… it’s… the Brazilian Centre for Biological Material! (IP tango)

Bulgaria: Supreme Administrative Court: additional term to respond or amend preclusive: Vitreo v. Bulgarian Patent Office (Kluwer Patent Blog)

Canada: World AIDS Day brings calls for legislative caution, reform (IP Watch)

EU: EMA publishes guidelines for biosimilar antibodies (Part I – Patent Docs), (Part II – Patent Docs)

EU: AstraZeneca and Nycomed raid by EU antitrust officials (GenericsWeb)

India: Supreme Court dismisses Bayer’ petition in patent linkage matter (Generic Pharmaceuticals and IP) (Spicy IP) (GenericsWeb) (SiNApSE)

India: Demand for changes in patent law rejected (Generic Pharmaceuticals and IP)

India: NGOs set up blog for FTA’s effects on access to medicine (Spicy IP)

Israel: Amending claims after an opposition is filed in Israel – Teva opposition to Schwartz’ patent covering ‘Stable salts of novel derivatives of 3-3 diphenylpropylamines’ (IP Factor)

Italy: New policy for the Italian drugs agency on the disclosure of information on Gx applications (Kluwer Patent Blog)

US: Patenting information – diagnostic method claims come under increased scrutiny (Patent Docs)

US: American Medical Association et al. file amici brief arguing for affirmance of AMP v. PTO (Holman’s Biotech IP Blog)

US: Myriad and the ACLU disagree over claim scope, but apparently not over patent eligibility of genetic diagnostic methods: AMP v. PTO (Holman’s Biotech IP Blog)

US: District Court N D Illinois: False marking intent to deceive may be alleged generally under FRCP 9(b), regardless of the deceived ‘public’s’ sophistication: Simonian v. Allergan, Inc (Docket Report)


Enbrel (Etanercept) – Israel: Patent status in question, in need of legislative fix (America-Israel Patent Law)

Fabrazyme (Alpha-galactosidase) – US: Statements by KEI and others on NIH rejection of Fabrazyme march-in request (KEI)

Intuniv (Guanfacine) – US: Impax confirms patent challenge relating to Intuniv (GenericsWeb)

Lovenox (Enoxaparin) – US: Momenta sues Teva over claims relating to ways of manufacturing and analysing structure of Enoxaparin (IPBiz) (SmartBrief)

Lunesta (Eszopiclone) – US: Teva and Sunovion settle Lunesta patent suit (Patent Docs)

Neupogen (Filgrastim) – US: Amgen’s bid for summary judgment in Neupogen suit with Teva falls short (Patent Docs)

Nexavar (Sorafenib) – India: Justice Ravindra Bhat frames ‘issues’ in Nexavar patent infringement dispute before the Delhi High Court (Spicy IP)

Nexium (Esomeprazole) – EU: AstraZeneca’s Nexium target in EU antitrust probe (GenericsWeb)

Olmesartan medoxomil and Hydrochlorothiazide – UK: ‘No, no, Novartis’, says court, you can’t join in!: Daiichi Sankyo Co Ltd v Comptroller General of Patents (The SPC Blog)

Coversyl (Perindopril) – Australia: FCAFC: Servier denied patent amendment on appeal: Les Laboratoires Servier v Apotex (Patentology)

Prandin (Repaglinide) – US: Paddock fails to dismiss Novo’s Prandin patent suit (Patent Docs)

Spiriva (Tiotropium bromide monohydrate) – Israel: Patent status in question, in need of legislative fix (America-Israel Patent Law)

Temodar (Temozolomide) – US: Jewish law in CAFC jurisprudence: Cancer Research Technology et al. v Barr Laboratories et al. (America-Israel Patent Law)

Ziagen (Abacavir) – US: Mylan’s Matrix receives tentative FDA approval under PEPFAR for Abacavir Sulfate tablets, 60 mg (SmartBrief)

%d bloggers like this: